Lenus Therapeutics, LLC Report issue

For profit Phase 2
Founded: Princeton NJ United States (2018)
Status: No NME R&D (2018)

Organization Overview

First Clinical Trial
2018
NCT03578029
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Lenus Therapeutics, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

rgn-137 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Epidermolysis Bullosa, Junctional (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1